Tags

Type your tag names separated by a space and hit enter

Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
J Clin Oncol. 2005 Sep 01; 23(25):6149-56.JC

Abstract

PURPOSE

To evaluate the therapeutic benefit of postchemotherapy retroperitoneal lymph node dissection (PCRPLND) in patients with persistently elevated serum tumor markers.

PATIENTS AND METHODS

One hundred fourteen patients with metastatic germ cell cancer with elevated serum tumor markers after first-line (50 patients) or second-line chemotherapy (64 patients) who underwent PCRPLND between 1977 and 2000 with a minimum follow-up of 2-years were included in this retrospective study.

RESULTS

The 5-year overall survival was 53.9%. Sixty-one patients (53.5%) are alive with a medium follow-up of 72 months. Fifty-three patients died of disease, with a medium time to death of 8.0 months. Mean preoperative serum alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (betaHCG) levels were 483 ng/mL and 555 mU/mL, respectively, with no difference in 5-year survival (P = .2). Retroperitoneal pathology revealed germ cell cancer in 53.5% of patients, teratoma in 34.2% of patients, and fibrosis in 12.2% of patients, with 5-year survival rates of 31.4%, 77.5%, and 85.7%, respectively (P < .0001). Predictors of retroperitoneal pathology included an increasing serum AFP or betaHCG, betaHCG more than 100 ng/mL, redo retroperitoneal lymph node dissection (RPLND), and second-line chemotherapy. Poor prognostic variables by multivariable analysis included betaHCG status, serum AFP level, redo RPLND, and germ cell cancer in the resected specimen.

CONCLUSION

A subset of patients with elevated serum tumor markers after chemotherapy is curable with surgery. The prognostic factors predictive of outcome in this analysis include an increasing betaHCG, serum AFP level, redo RPLND, and germ cell cancer in the resected specimen. These factors, along with clinical and surgical experience, should aid in determining the appropriate integration of surgery and chemotherapy in this population.

Authors+Show Affiliations

Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. stdbeck@iupui.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16135481

Citation

Beck, Stephen D W., et al. "Outcome Analysis for Patients With Elevated Serum Tumor Markers at Postchemotherapy Retroperitoneal Lymph Node Dissection." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 23, no. 25, 2005, pp. 6149-56.
Beck SD, Foster RS, Bihrle R, et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2005;23(25):6149-56.
Beck, S. D., Foster, R. S., Bihrle, R., Einhorn, L. H., & Donohue, J. P. (2005). Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 23(25), 6149-56.
Beck SD, et al. Outcome Analysis for Patients With Elevated Serum Tumor Markers at Postchemotherapy Retroperitoneal Lymph Node Dissection. J Clin Oncol. 2005 Sep 1;23(25):6149-56. PubMed PMID: 16135481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. AU - Beck,Stephen D W, AU - Foster,Richard S, AU - Bihrle,Richard, AU - Einhorn,Lawrence H, AU - Donohue,John P, PY - 2005/9/2/pubmed PY - 2005/9/21/medline PY - 2005/9/2/entrez SP - 6149 EP - 56 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 23 IS - 25 N2 - PURPOSE: To evaluate the therapeutic benefit of postchemotherapy retroperitoneal lymph node dissection (PCRPLND) in patients with persistently elevated serum tumor markers. PATIENTS AND METHODS: One hundred fourteen patients with metastatic germ cell cancer with elevated serum tumor markers after first-line (50 patients) or second-line chemotherapy (64 patients) who underwent PCRPLND between 1977 and 2000 with a minimum follow-up of 2-years were included in this retrospective study. RESULTS: The 5-year overall survival was 53.9%. Sixty-one patients (53.5%) are alive with a medium follow-up of 72 months. Fifty-three patients died of disease, with a medium time to death of 8.0 months. Mean preoperative serum alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (betaHCG) levels were 483 ng/mL and 555 mU/mL, respectively, with no difference in 5-year survival (P = .2). Retroperitoneal pathology revealed germ cell cancer in 53.5% of patients, teratoma in 34.2% of patients, and fibrosis in 12.2% of patients, with 5-year survival rates of 31.4%, 77.5%, and 85.7%, respectively (P < .0001). Predictors of retroperitoneal pathology included an increasing serum AFP or betaHCG, betaHCG more than 100 ng/mL, redo retroperitoneal lymph node dissection (RPLND), and second-line chemotherapy. Poor prognostic variables by multivariable analysis included betaHCG status, serum AFP level, redo RPLND, and germ cell cancer in the resected specimen. CONCLUSION: A subset of patients with elevated serum tumor markers after chemotherapy is curable with surgery. The prognostic factors predictive of outcome in this analysis include an increasing betaHCG, serum AFP level, redo RPLND, and germ cell cancer in the resected specimen. These factors, along with clinical and surgical experience, should aid in determining the appropriate integration of surgery and chemotherapy in this population. SN - 0732-183X UR - https://www.unboundmedicine.com/medline/citation/16135481/Outcome_analysis_for_patients_with_elevated_serum_tumor_markers_at_postchemotherapy_retroperitoneal_lymph_node_dissection_ L2 - http://ascopubs.org/doi/full/10.1200/JCO.2005.11.684?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -